Fusion of peptides or proteins with intrinsic short half-life to human serum albumin (HSA) represents a proven strategy to increase the half-life of these biopharmaceuticals allowing for less frequent administration while maintaining efficacy. Meanwhile, recombinant albumin fusion technology has been successfully applied to various proteins and peptides. Albiglutide, a recombinant glucagon-like peptide-1 dimer fused to human albumin (GLP1-GLP1-HSA) has recently obtained US FDA (Tanzeum) and EMA (Eperzan) approvals and various other proteins and peptides fused to HSA are in clinical and pre-clinical development.

VALIODGEN´s well-established Pichia protein production toolbox facilitates high-yield production of albumin-fusion proteins using robust, reproducible and scalable processing methods.

HSA-fusion proteins produced with VALIDOGEN´s Pichia pastoris toolbox can be secreted very efficiently (5-20 g/l) resulting in reduced production costs at the same time increasing the profitability of a therapeutic product and maintaining quality. 

Titers of up to 35 g/l of recombinant albumins

Titers of up to 35 g/l of recombinant albumins as achieved with VALIDOGEN's UNLOCK PICHIA technology, constitute the highest values (reported to date) of recombinant proteins secreted into the culture supernatant of yeast cultivations. 2^nd generation AOX1 promoter variants, facilitating methanol-free processing, also deliver double-digit g/l levels of HSA in glycerol-only driven fermentations.

 

Key benefits

• Exceptionally high product yields of albumins and albumin fusion proteins
• Robust, scalable processes
• Proven and clinically validated production technology

 

 

Further elements of UNLOCK PICHIA - VALIDOGEN's Pichia pastoris protein production toolbox